Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146217 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection
A Phase 2 study, sponsored by Saptalis Pharmaceuticals.
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07146217 is a Phase 2 study that has not yet begun recruiting, run by Saptalis Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT07146217, a Phase 2 study, has not yet begun recruiting, sponsored by Saptalis Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is an open-label, single-arm, pharmacokinetic and safety study of Likmez® in pediatric patients aged 12 months to \<4 years with anaerobic bacterial infection
Interventions
- DRUG Likmez® (metronidazole) Oral Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-08 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07146217
The ClinicalTrials.gov registry entry for NCT07146217 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saptalis Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Likmez® (metronidazole) Oral Suspension is the first listed.
NCT07146217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07146217 about?
NCT07146217 is a clinical study titled "Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection". This is an open-label, single-arm, pharmacokinetic and safety study of Likmez® in pediatric patients aged 12 months to \<4 years with anaerobic bacterial infection
What is the current status of trial NCT07146217?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-08. Estimated completion is 2026-10.
What interventions are being tested in trial NCT07146217?
The interventions under investigation include: Likmez® (metronidazole) Oral Suspension (DRUG).
Who is sponsoring clinical trial NCT07146217?
This trial is sponsored by Saptalis Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.